FDA
-
-
-
-
-
-
-
TG Therapeutics reports positive Phase 1 subcutaneous BRIUMVI trial results
-
-
-
-
-
-
-
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
-
-
-
-
-
-
-
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
-
-
-
-
-
-
-
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
-
-
-
-
-
-
-
TG Therapeutics presents BRIUMVI data at multiple sclerosis forum
-
-
-
-
-
-
-
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
-
-
-
-
-
-
-
TG Therapeutics reports six-year BRIUMVI data at ECTRIMS conference
-
327,057 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

